We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Magnetic Nanoparticles Simultaneously Diagnose, Monitor, and Treat Diseases

By LabMedica International staff writers
Posted on 21 Nov 2009
Tiny magnetic nanoparticles (mNPs) and external magnetic forces create a medical means to confirm specific ailments and automatically release healing drugs while inside a living system. For example, mNPs can direct ”therapeutically armed” white blood cells to invade a tumor's territory, or they can target specific nerve channels and induce nerve-led behavior (such as heart beating).

The magnetic component of the direction-giving nanoparticles is usually an iron-based compound called ferric oxide, which is coated in a biocompatible surface, sometimes using, for example, fatty acids, to provide stability during the particles journey through the body. For biomedicine, the particles are useful because specific signal triggering molecules can be added to identify certain conditions, or dyes to help in medical imaging, or therapeutic agents to remedy a wide range of conditions.

Multifunctional particles, modeled on viral particles such as the flu and human immunodeficiency virus (HIV), are being studied and developed to carry signal-generating sub-molecules and drugs.

A number of review articles dealing with progress in the use of mNPs in biomedicine as well as their future prospects were published on November 6, 2009 in IOP Publishing's Journal of Physics D.

Professor Q. Pankhurst from the department of physics and astronomy at the University College London (UK) and colleagues were authors of one of the reviews, which dealt with the progress in applications of mNPs. In their conclusion they wrote, "there is a lot of activity in this field, and the future is bright, so long as we pay attention to the primary criteria for success, making sure that there is a clearly identified clinical need that can be addressed, and addressed in a way that can be quantified or assessed to the satisfaction of the relevant licensing bodies.''

Related Links:

University College London



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA

Latest Clinical Chem. News

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
21 Nov 2009  |   Clinical Chem.

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
21 Nov 2009  |   Clinical Chem.

Low-Cost Portable Screening Test to Transform Kidney Disease Detection
21 Nov 2009  |   Clinical Chem.